Kim Kardashian West endorsement for morning sickness pills now has drugmaker in trouble with the FDA

At this point, it’s pretty clear that whatever Kim Kardashian West posts on her social media feeds will be seen by millions of followers, and chances are that an endorsement will be met with some returns.

The pregnant Kardashian promoted a morning sickness medication called Diclegis, which is produced by the Pennsylvania-based pharmaceutical company Duchesnay, on Instagram, Twitter and Facebook last month. The company later released a statement about a partnership.

The only problem is, when telling all of her followers about the drug, she didn’t happen to mention the potential risks and regulations, which according to the FDA, is misleading and now the drug company is getting some heat via an official warning.

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Here’s a clip from the FDA’s warning concerning one of Kardashian’s post, which has since been deleted.

The FDA letter sent to Duchesnay is dated Aug. 7, and the company will have to stop selling the drug unless they stop “misbranding” it before Aug. 21.

According to Bloomberg, a Duchesnay spokesperson said the company “acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations.” Duchesnay “will take quick action in responding to the FDA’s letter and immediately and effectively address any issues.”

When it comes to celebrities of this caliber (for better or worse), what might appear to be quick hit Tweets or Facebook statuses are likely discussed with their management to cover legal bases and such, but that doesn’t mean they can’t get other people in trouble.